Af­ter first-line ap­proval in DL­B­CL, de­bate con­tin­ues around ben­e­fit from Roche's ADC Po­livy

The FDA ap­proved Roche and Genen­tech’s an­ti­body-drug con­ju­gate Po­livy in April as a first-line treat­ment for dif­fuse large B-cell lym­phoma (DL­B­CL) along­side a chemother­a­py reg­i­men R-CHP.

The ap­proval came de­spite mod­est ef­fi­ca­cy in a Phase III study and FDA ques­tions about the ther­a­py, though an ad­vi­so­ry com­mit­tee large­ly sup­port­ed ap­prov­ing the drug.

It al­so in­tro­duced a new first-line op­tion for DL­B­CL, where the chemother­a­py reg­i­men R-CHOP has been the stan­dard care op­tion for decades.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER